AUROPHARMA:NSE:NSE-Aurobindo Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1297.5

Change

-15.30 (-1.17)%

Market Cap

USD 737.59B

Volume

1.33M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

+16.30 (+0.28%)

USD 1,561.24B
MANKIND:NSE Mankind Pharma Ltd

+35.15 (+1.22%)

USD 1,185.39B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+1.20 (+0.09%)

USD 1,157.53B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+41.15 (+1.22%)

USD 1,152.44B
LUPIN:NSE Lupin Limited

-2.65 (-0.11%)

USD 1,016.49B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

+39.40 (+4.10%)

USD 978.76B
ALKEM:NSE Alkem Laboratories Limited

+35.80 (+0.65%)

USD 665.89B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

+18.30 (+1.13%)

USD 447.54B
IPCALAB:NSE IPCA Laboratories Limited

+17.05 (+0.99%)

USD 421.90B
AJANTPHARM:NSE Ajanta Pharma Limited

+51.00 (+1.73%)

USD 380.23B

ETFs Containing AUROPHARMA:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.12% 15% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.12% 15% F 21% F
Trailing 12 Months  
Capital Gain 15.88% 37% F 54% F
Dividend Return 0.13% 5% F 8% B-
Total Return 16.02% 37% F 54% F
Trailing 5 Years  
Capital Gain 183.92% 40% F 48% F
Dividend Return 4.87% 47% F 34% F
Total Return 188.79% 40% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 23.65% 42% F 35% F
Dividend Return 24.36% 43% F 35% F
Total Return 0.71% 68% D+ 53% F
Risk Return Profile  
Volatility (Standard Deviation) 60.35% 35% F 39% F
Risk Adjusted Return 40.36% 32% F 22% F
Market Capitalization 737.59B 92% A 93% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.